Vildagliptin: the first innovative DDP-4 inhibitor

A review of the main stages of investigation undertaken by Novartis Pharmaceuticals in search of a new molecule for the treatment of type 2 diabetesmellitus, dipeptidyl peptidase-4 (DPP-4) inhibitor (Vildaglyptin). The data on specificity and selectivity of the action of this molecule are presenteda...

Description complète

Enregistré dans:
Détails bibliographiques
Auteur principal: Edvin Villkhauer
Format: article
Langue:EN
RU
Publié: Endocrinology Research Centre 2010
Sujets:
Accès en ligne:https://doaj.org/article/9ab778ef5d4d43219fab7fe831ded6ca
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!